Trade Scholar Rock Holding Corp - SRRK
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Latest shares articles

Take-Two heads into GTA VI launch with a weaker quarter and full-year outlook unchanged
Take-Two’s Q2 Net Bookings came in below guidance, but GTA VI pre-orders are at ‘unprecedented levels’. What the launch could mean for TTWO stock.
13:30, 19 November 2026

Nvidia results preview: what to expect from Q3 after the AI sell-off
Revenue guidance of USD 108bn, a new interim CEO and an AI sell-off: what investors are watching as Nvidia reports its fiscal Q3 2027 results.
12:06, 17 November 2026

What you need to know about Alphabet after the biggest one-day drop in its history – break-down
Google Cloud is growing fast, but AI spending pushed Alphabet’s free cash flow negative. A full break-down of results, valuation, debt and risks for GOOGL
11:53, 13 November 2026

Amazon's USD 220bn bet: how record AI spending could reshape the company
Amazon plans about USD 220bn of capex in 2026. We look at AWS, profitability, debt, valuation and the key catalysts and risks for AMZN shares.
10:50, 6 November 2026
Related News